Breast Cancer Research and Treatment最新文献

{"title":"Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.","authors":"Peter W Heger, Dirk Hotz, Matthias Kalder, Karel Kostev","doi":"10.1007/s10549-025-07711-9","DOIUrl":"10.1007/s10549-025-07711-9","url":null,"abstract":"<p><strong>Aims: </strong>The special extract ERr 731 from the roots of rhapontic rhubarb has been prescribed for women with menopausal symptoms for more than 30 years. The aim of the present study is to evaluate the association between ERr 731 therapy and subsequent breast cancer in women in a real-world setting. ERr 731 users were compared to women without this therapy as well as women receiving hormone therapy.</p><p><strong>Methods: </strong>This retrospective cohort study included data of women treated by 260 office-based gynecologists in Germany who received a prescription for ERr 731 between 1993 and 2022 (IQVIA Disease Analyzer database). These women were matched to women without ERr 731 prescriptions as well as women with hormone replacement therapy (HRT) prescriptions (1:3) using nearest neighbor propensity scores. A univariate Cox regression analysis was conducted to evaluate the associations between ERr 731 prescription and breast cancer risk compared to women without ERr 731 prescription and women with HRT prescriptions.</p><p><strong>Results: </strong>A total of 5,686 women with versus 17,058 women without ERr 731 prescription were available for the first analysis, and 2,616 women with ERr 731 prescription (a proportion of the 5,686 women used in the first analysis) and 7,848 women with HRT prescriptions for the second (average age 52-53 years). ERr 731 was not associated with an increased risk of breast cancer diagnosis when the group of women with ERr 731 prescription was compared to women without (OR: 1.01, 95% CI: 0.81-1.26) or to that of women with HRT prescription ((OR: 0.96, 95% CI: 0.69-1.33). No associations were observed in age-stratified analyses or in women with and without menopausal or other perimenopausal disorders.</p><p><strong>Conclusion: </strong>The present study provides strong evidence that ERr 731 is not associated with an increased risk of breast cancer diagnosis compared to both non-users and HRT users. Given its favorable safety profile, ERr 731 may represent a viable alternative to HRT, particularly for women concerned about breast cancer risk.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"139-148"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Our response to the letter to the editor for the article \"Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis\".","authors":"Ruşen Coşar, Necdet Süt","doi":"10.1007/s10549-025-07688-5","DOIUrl":"10.1007/s10549-025-07688-5","url":null,"abstract":"<p><p>They expressed their concerns about making comments regarding the sample size in our study. The preferred propensity score analysis was the statistical method chosen because it is the analysis after balancing the small number of patients with the much larger number of patients in this situation in terms of both number and prognostic factors. In fact, the reference to future studies on this subject has been made for new retrospective series rather than prospective randomized studies. We wanted to draw the attention of researchers to propensity score analysis and to show that future retrospective series studies can ask questions with clearer answers using propensity score analysis.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"185-186"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy.","authors":"Anne Perdrix, Nathalie Olympios, Jean Rouvet, Marie Degremont, Camille Fontaine, Baptiste Boitel, Roman Vion, Marianne Leheurteur, Florian Clatot","doi":"10.1007/s10549-025-07702-w","DOIUrl":"10.1007/s10549-025-07702-w","url":null,"abstract":"<p><strong>Purpose: </strong>Pembrolizumab plus neoadjuvant chemotherapy (P-CT) is the new standard in early-stage triple-negative breast cancers (TNBC). Pembrolizumab impact on ovarian reserve remained unknown. We evaluated the impact of pembrolizumab on ovarian reserve, through plasmatic Anti-Müllerian (AMH) analysis, in young TNBC patients.</p><p><strong>Methods: </strong>TNBC patients < 43 years treated by P-CT (carboplatin/paclitaxel/epirubicin/cyclophosphamide plus pembrolizumab) of which plasma samples were available before and after treatment were included retrospectively (P-CT group). AMH, FSH, and estradiol were analyzed before and after treatment, then compared to a retrospective cohort of TNBC patients treated with chemotherapy alone (cyclophosphamide/anthracycline/taxanes) (No-P group).</p><p><strong>Results: </strong>P-CT patients (N = 17) and No-P patients (N = 62) had comparable median age, BMI, smoking exposure, BRCA status, oral hormonal contraceptive use at diagnosis, and baseline AMH. Drugs used were comparable in both groups, except for carboplatin and pembrolizumab, only used in P-CT group. One year after the start of treatment, AMH fell from 1.08 to 0.01 ng/mL (p = 0.0001) and from 1.39 to 0.018 ng/mL (p < 0.0001), in the P-CT and No-P groups, respectively, without difference according to pembrolizumab exposure (p = 0.25). 9/17 P-CT patients (53%), and 21/62 No-P patients (34%), had undetectable AMH after treatment (p = 0.25). FSH and estradiol were comparable between the two groups, before and after treatment.</p><p><strong>Conclusion: </strong>No additional impact of pembrolizumab versus chemotherapy alone on AMH evolution was observed in TNBC patients < 43 years. Nevertheless, undetectable AMH 1 year after the start of treatment was common in the P-CT group. Larger studies are essential to confirm these preliminary results and assess long-term impact of pembrolizumab on ovarian reserve.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"79-86"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer.","authors":"Ismail Ajjawi, Alejandro Rios, Wei Wei, Tristen S Park, Maryam B Lustberg","doi":"10.1007/s10549-025-07725-3","DOIUrl":"10.1007/s10549-025-07725-3","url":null,"abstract":"<p><strong>Purpose: </strong>Immunotherapy has emerged as a promising treatment for metastatic triple-negative breast cancer (mTNBC), yet factors influencing its adoption remain unclear. This study examines clinical, sociodemographic, and facility-related determinants of immunotherapy use in mTNBC patients using the National Cancer Database (NCDB).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of mTNBC patients from the NCDB (2015-2020), categorizing them into immunotherapy recipients and non-recipients. Patients with missing data on key variables were excluded. Univariable and multivariable logistic regression identified factors influencing immunotherapy adoption. Cox proportional hazards regression and log-rank tests assessed overall survival.</p><p><strong>Results: </strong>Among 1,887 mTNBC patients, 232 (12.2%) received immunotherapy. Factors positively associated with immunotherapy use included later diagnosis year (2018-2020: OR 5.35, p < 0.001), academic facilities (OR 1.43, p = 0.044), and private insurance (OR 1.34, p < 0.001). Lower likelihood of immunotherapy use was observed in older age (71+: OR 0.49, p = 0.019), rural facilities (OR 0.43, p = 0.042), Black race (OR 0.73, p = 0.039), Hispanic ethnicity (OR 0.53, p = 0.026), and higher Charlson comorbidity scores (≥ 2: OR 0.31, p = 0.035). Immunotherapy was associated with significantly improved survival (median 2.21 vs. 1.01 years, log-rank p < 0.001) and reduced mortality risk (HR 0.59, p < 0.001).</p><p><strong>Conclusion: </strong>Immunotherapy use in mTNBC has increased in recent years, with clinical, sociodemographic, and facility-related factors influencing its adoption. Our findings highlight the importance of addressing disparities in access to immunotherapy to ensure equitable treatment and better survival outcomes for all mTNBC patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"299-308"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques.","authors":"Shing Fung Lee, Henry C Y Wong, Jolien Robijns, Stephen Lowell B Ciocon, Paula Elaine Diniz Dos Reis, Sarina Sadeghi, Muna Al-Khaifi, Mami Ogita, Adrian W Chan, Agata Rembielak, Daniel Livesey, Matthew Chong, Zhihui Amy Liu, Mark Trombetta, Wee Yao Koh, Yiat Horng Leong, Gustavo N Marta, Pierluigi Bonomo, Viola Salvestrini, Vassilios Vassiliou, Pradnya Chopade, Partha Patel, Cindy Wong, Julie Ryan Wolf, Corina van den Hurk, Raymond J Chan, Michael Jefford, Edward Chow, Jennifer Yin Yee Kwan","doi":"10.1007/s10549-025-07700-y","DOIUrl":"10.1007/s10549-025-07700-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study assessed the impact of radiotherapy (RT) techniques on chronic skin reactions and health-related quality of life (HRQoL) in breast cancer patients, comparing conventional RT with modern techniques such as intensity-modulated RT (IMRT).</p><p><strong>Methods: </strong>A comprehensive search was conducted in Embase, MEDLINE, and Cochrane CENTRAL from inception to April 26, 2024. Conventional RT, which uses 2D or 3D imaging to shape radiation beams without dynamic intensity modulation, was compared with alternate RT techniques for adjuvant breast cancer treatment. Primary outcomes included chronic grade ≥ 2 skin toxicities (hyperpigmentation, breast fibrosis, telangiectasia, edema, and atrophy/retraction) and HRQoL, assessed mainly with EORTC QLQ-C30 and QLQ-BR23 modules. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model.</p><p><strong>Results: </strong>From 1305 screened studies, nine articles representing seven studies (2418 patients), including three randomized controlled trials, met inclusion criteria. Most studies used conventional fractionation (45-50 Gray in 25 fractions). IMRT was associated with a lower incidence of chronic grade ≥ 2 hyperpigmentation (RR: 0.39, 95%CI: 0.17-0.89, I² = 0%) compared to conventional RT. No significant differences were found for grade ≥ 2 breast fibrosis, telangiectasia, edema, and atrophy/retraction. Cosmetic outcomes from IMRT were favorable in the short term, with no long-term differences. Three studies reported no significant HRQoL differences between IMRT and conventional RT.</p><p><strong>Conclusion: </strong>IMRT may reduce certain chronic skin toxicities compared to conventional RT. However, consistent long-term differences in cosmetic outcomes or HRQoL were not observed. These findings are limited by the small number of studies and variability in reporting standards.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients.","authors":"Kirsten M Woolpert, Thomas P Ahern, James W Baurley, Maret L Maliniak, Per Damkier, Anders Kjærsgaard, Lindsay J Collin, Stephen Hamilton-Dutoit, Trine Tramm, Bent Ejlertsen, Henrik T Sørensen, Timothy L Lash, Deirdre P Cronin-Fenton","doi":"10.1007/s10549-025-07719-1","DOIUrl":"10.1007/s10549-025-07719-1","url":null,"abstract":"<p><strong>Purpose: </strong>Premenopausal, estrogen receptor (ER)-positive breast cancer patients should receive tamoxifen for at least 5 years, but many prematurely discontinue. Activation, transport, and deactivation of tamoxifen and its metabolites are controlled by proteins encoded by genes with functional variations. We examined the impact of genetic polymorphisms in the tamoxifen pathway on early treatment discontinuation.</p><p><strong>Methods: </strong>We included premenopausal women diagnosed with ER-positive breast cancer (2002-2011) in Denmark who initiated tamoxifen. We genotyped 26 genetic variants in 15 enzymes involved in tamoxifen metabolism. Early discontinuation was defined as tamoxifen use for < 5 years. We estimated individual and combined effects of genetic variants using a Bayesian pathway approach. We report Bayes Factors (BF), wherein values > 1 indicate support of an effect of the genetic pathway on discontinuation (compared with no effect).</p><p><strong>Results: </strong>Among 3,729 patients, 536 (14%) discontinued tamoxifen within 5 years. Genetic variants involved in tamoxifen activation impacted early discontinuation (BF = 7.5), in a manner driven almost entirely by CYP2D6 activity (BF = 22.6). Several variants in CYP2D6 and transporter genes synergistically increased the hazard of early discontinuation (e.g., CYP2D6*2 and ABCC2; BF = 138).</p><p><strong>Conclusions: </strong>Variants in enzymes responsible for activating tamoxifen metabolites-particularly within CYP2D6-influence early tamoxifen discontinuation. CYP2D6 variants synergistically interact with transporter gene variants, namely ABCC2, to further raise the risk of discontinuation.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"251-260"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone-associated dietary patterns and premenopausal breast cancer risk.","authors":"Sable N Fest, Leslie V Farland, David R Doody, A Heather Eliassen, Bernard A Rosner, Teresa T Fung, Susan E Hankinson, Thomas W Kensler, Walter C Willett, Holly R Harris","doi":"10.1007/s10549-025-07689-4","DOIUrl":"10.1007/s10549-025-07689-4","url":null,"abstract":"<p><strong>Purpose: </strong>Circulating levels of sex steroid hormones have previously been associated with premenopausal breast cancer risk. Few studies have considered the association between dietary patterns and premenopausal hormone levels. Our objective was to derive dietary patterns associated with premenopausal hormone levels and investigate the association between pattern scores and premenopausal breast cancer risk.</p><p><strong>Methods: </strong>Using reduced rank regression among a subset of participants from the Nurses' Health Study II (NHSII) (n = 8,962), we identified dietary patterns correlated with premenopausal levels of five sex steroid hormones measured in the follicular and luteal phases. Then, in the full NHSII cohort (n = 90,341), we used Cox proportional hazards models to calculate hazard ratios (HRs) for breast cancer risk associated with each dietary pattern score.</p><p><strong>Results: </strong>Dietary patterns were identified for luteal estradiol, luteal free estradiol, follicular estrone, luteal estrone, and free testosterone. However, these patterns explained a low percent variation in individual hormone levels, ranging from 2.5-4.1%. During 24 years of follow-up, 1,956 premenopausal breast cancer cases were ascertained. Dietary patterns associated with luteal free estradiol (HR for fifth versus first quintile = 1.29; 95% CI = 1.11-1.49; P_trend < 0.01) and follicular estrone (HR for fifth versus first quintile = 1.28; 95% CI = 1.10-1.49; P_trend < 0.01) were positively associated with premenopausal breast cancer risk.</p><p><strong>Conclusion: </strong>Our findings indicate that while some dietary factors may marginally influence premenopausal hormone levels, the relation between sex steroid hormones and premenopausal breast cancer risk is likely not driven by diet. Future studies should consider other mechanisms through which diet may impact breast cancer risk, including inflammatory processes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"23-35"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive lobular breast carcinoma variants; clinicopathological features and patient outcomes.","authors":"Aysegul Aktas, Meryem Gunay Gurleyik, Dogukan Akkus, Zekeriya Ucur, Fugen Aker","doi":"10.1007/s10549-025-07729-z","DOIUrl":"10.1007/s10549-025-07729-z","url":null,"abstract":"<p><strong>Introduction: </strong>An understanding of the differences among the invasive lobular breast carcinoma (ILC) variants is crucial for risk stratification, and tailored treatment planning. This article compares variants of ILC according to their clinical outcomes and histopathological features.</p><p><strong>Patients and methods: </strong>Patients diagnosed with ILC between January 2010 and August 2021 were retrospectively evaluated. Patients were divided into three groups; 1: classic ILC (cILC); 2: pleomorphic lobular carcinoma (PLC); 3: mixed ILC. Mixed ILC was divided into three subgroups: 3a, cILC + PLC; 3b, cILC + mixed; 3c, PLC + mixed.</p><p><strong>Results: </strong>A total of 254 patients were included in the study. Median overall survival (OS) was 48 months, and median disease-free survival (DFS) was 46 months. Locoregional recurrence (LRR) occurred in 15 (5.9%) of the patients, and distant metastasis (DM) developed in 23 (9.1%). Death occurred in 16 (6.3%) patients. There was no significant difference in LRR rate among groups. When considering five groups (Groups 1, 2, 3a, 3b, and 3c), the median OS was 62.5, 52.0, 50.8, 56.7, and 41.5 months, respectively, while the median DFS was 60.3, 46.6, 46.7, 54.5, and 39.6 months, respectively. Notably, the PLC + mixed group without a classic variant (Group 3c) exhibited even worse outcomes than pure PLC.</p><p><strong>Conclusions: </strong>In this study, pure cILC exhibited the best prognostic features among the ILC variants. Furthermore, we observed a higher mastectomy rate in patients with pleomorphic variants. Surgical management of ILC remains controversial. Moreover, comprehensive randomized controlled trials are essential to establish standardized treatment protocols for ILC patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"347-359"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable LA/MBC: final results of the ESTHER study.","authors":"Alistair Ring, Stephanie Sutherland, Catherine Harper-Wynne, James Owen, Thibaut Sanglier, Galina Velikova","doi":"10.1007/s10549-025-07708-4","DOIUrl":"10.1007/s10549-025-07708-4","url":null,"abstract":"<p><strong>Purpose: </strong>There are multiple contemporary systemic therapy options for patients with HER2-positive advanced breast cancer. However, there are few longitudinal data regarding what proportion of patients go on to receive later lines of therapy, real-world outcomes and the impact of brain metastases. We therefore conducted a prospective, multicentre non-interventional study to describe the anti-cancer treatment regimens used and clinical outcomes in patients with HER2-positive advanced breast cancer across multiple lines of therapy undergoing treatment in routine clinical care.</p><p><strong>Methods: </strong>Adult patients diagnosed with HER2-positive advanced breast cancer were recruited to a prospective, multicentre non-interventional study to observe treatment patterns and outcomes.</p><p><strong>Results: </strong>Three hundred and eleven patients were recruited with median age 57 years. Of those patients initiating first, second-, and third-line treatment, 72 (23.2%), 59 (41.3%), and 20 (35%), respectively had passed away without advancing on to subsequent lines of therapy. The median progression-free survival in the first line was 25.8 months and overall survival 56.7 months. Over the course of the study 107 (34.4%) of participants were diagnosed with CNS metastases. Median overall survival from diagnosis of brain metastases was 15.4 months.</p><p><strong>Conclusions: </strong>Many patients treated in routine practice may not get to benefit from contemporary second and later line treatments, where brain metastases become increasingly common. These findings have implications for selection of optimal systemic therapy sequencing in advanced HER2-positive breast cancer.</p><p><strong>Clinical trial registration: </strong>This study was approved by Nottingham Research Ethics Committee on 29th December 2014.</p><p><strong>Clinical trial registration: </strong>NCT02393924.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"113-121"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.","authors":"Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir","doi":"10.1007/s10549-025-07722-6","DOIUrl":"10.1007/s10549-025-07722-6","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.</p><p><strong>Methods: </strong>A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.</p><p><strong>Results: </strong>104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.</p><p><strong>Conclusion: </strong>Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"269-276"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}